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Identification of genetic factors predisposing to cutaneous
melanoma (CM) has been the subject of considerable effort
by many laboratories worldwide. Despite this, relatively few
genetic factors mediating susceptibility to and/or prognosis
in sporadic CM have been identified with certainty, although
the literature contains a number of claimed associations.
For example, polymorphisms associated with the me-
lanocortin-1 receptor (MCR1) (Valverde et al, 1996; Ken-
nedy et al, 2001), CDKN2A (Kumar et al, 2001), XRCC3 DNA
repair (Winsey et al, 2000) genes, and glutathione S-transf-
erase Mu phenotype (GSTM1) (Lafuente et al, 1995) may be
associated with susceptibility to CM. Polymorphisms asso-
ciated with the Vitamin D receptor and the cytochrome
P450 CYP2D6 genes have been implicated in modulating
prognosis in this tumor (Strange et al, 1999; Hutchinson et
al, 2000). Several lines of evidence also suggest that CM
patients develop an immune response to their tumors (Wolf-
el et al, 1993), supported by variable HLA-DQB1 allelic as-
sociations with CM susceptibility and prognosis (Lee et al,
1994; Bateman et al, 1998). In addition, interleukin-10 (IL-
10) promoter genotypes may confer both susceptibility to
CM and act as risk factors for more advanced, invasive,
poorer prognosis disease (Howell et al, 2001) and poorer
survival (Martinez-Escribano et al, 2002), while gene poly-
morphisms associated with pro-angiogenic cytokines (in
particular, vascular endothelial growth factor (VEGF)) may
also play a role in predisposition to and tumor growth in CM
(Howell et al, 2002).
In the majority of these preliminary studies, probability
values and odds ratios (ORs) for association tend to be
modest, sample sizes small, and few—if any—independent
verifications have been performed, so most results should
be interpreted with caution. One such report (Shahbazi et al,
2002), demonstrating a highly significant association be-
tween a functional single nucleotide polymorphism (SNP) in
the epidermal growth factor (EGF) gene (chrom 4q25–q27)
and both susceptibility to/severity of this disease, generat-
ed considerable interest. In this study of 135 CM patients
and 99 controls, the EGFþ 61 GG genotype, associated
with elevated EGF expression, was associated with both
CM susceptibility (47.4% in cases vs 20.2% in controls;
po0.001; OR¼ 4.9) and tumor Breslow thickness as a sur-
rogate marker of prognosis (p¼ 0.045 for tumors with a
thickness ofX3.5 mm vso3.5 mm). This result is in agree-
ment with a putative role for EGF in melanomanesis, due to
its mitogenic and tumorigenic properties and action in pro-
liferation of epidermal tissues, but again was based on
analysis of a relatively small number of cases and controls.
Accordingly, a number of independent studies, including
a previous publication from our own laboratory (McCarron
et al, 2003), one very recent paper (Amend et al, 2004), and
two studies published in this issue (James et al, 2004;
Randerson-Moor et al, 2004) have sought independent
confirmation of the reported association between CM sus-
ceptibility and tumor Breslow thickness as a marker of dis-
ease severity and prognosis.
The small study (159 patients and 310 controls) pub-
lished by our group failed to demonstrate any association
between EGF þ61 genotype and CM susceptibility. How-
ever, this study did show a modest, but significant increase
in frequency of the GG genotype among patients with
tumors 43.5 mm thick (30% vs 9.8%; p¼0.03), although
the GG genotype was much less frequent among patients
with thicker tumors than in the original study by Shahbazi
et al (75.0%) (McCarron et al, 2003). The results from the
McCarron et al study should be treated with some caution,
since all patient genotyping was performed on DNA derived
from archival tissue blocks and results could therefore be
affected by any loss of heterozygosity for the EGF region
within the tumor, although the methodology employed
should be capable of detecting allelic sequences from sur-
rounding and infiltrating non-tumor cells. Results from the
two studies published in this issue (James et al, 2004;
Randerson-Moor et al, 2004) and the recent communication
in Cancer Research (Amend et al, 2004) are therefore of
particular value, since all analyses were performed on DNA
extracted from peripheral blood. Again, none of the three
studies demonstrated any association between EGF þ 61
genotype and susceptibility to CM. This is noteworthy, be-
cause the two studies published in this issue examined
considerably larger numbers of patients and controls (753
and 380 patients, compared with 2387 and 697 controls
respectively) than either of the earlier studies. In addition,
both of these studies report no EGF þ61 genotypic asso-
ciation with nevus phenotype or development not examined
hitherto, while the study by Amend et al (2004) did not show
any association with multiple versus single primary mel-
anoma status.
The three studies by Amend et al (2004), James et al
(2004) and Randerson-Moor et al (2004), however, report
conflicting findings with respect to EGF þ61 genotype and
tumor Breslow thickness. James et al (2004) report that CM
patients homozygous for the GG genotype do have thickerAbbreviation: CM, cutaneous melanoma
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tumors than GA or AA patients, in line with the original
findings of Shahbazi et al (2002) and McCarron et al (2003),
although the effect was small, but significant (p¼0.049).
Conversely, in the study by Randerson-Moor et al (2004),
the G allele was associated with decreased Breslow thick-
ness (p¼0.026), whereas in the study by Amend et al (2004)
no significant association between EGF þ61 genotype and
Breslow thickness was observed.
How might the discrepancies of links between EGF and
CM occurrence between the Shahbazi et al and four sub-
sequent studies be explained? First, could a differential
distribution of EGFþ61 genotypes in the study populations
be a contributing factor? All of these five studies, however,
were performed in Caucasian patients and controls, with
the studies by Shahbazi et al (2002), McCarron et al (2003)
and Randerson-Moor et al (2004) performed in patients from
a single European country (the United Kingdom). Genotype
distributions in the control series in all studies are in broad
agreement, as are genotype frequencies in four of the five
series of CM patients. Genotypes in CM patients are dis-
tributed differently in the study by Shahbazi et al (2002).
Second, differential patient selection may be a confounding
factor. The finding of an association between the GG gen-
otype and CM susceptibility in the Shahbazi et al (2002)
study might have arisen if the principal GG association were
with CM severity (as evidenced by Breslow thickness) rather
than susceptibility per se. This cannot be discounted and
certainly merits further investigation, but is perhaps ren-
dered less likely by the similar distributions of Breslow
thickness of tumors in those series for which data are in-
cluded. Third, discrepancies between these results might
be accounted for by other unknown polymorphisms in par-
tial linkage disequilibrium with the þ61 SNP being caus-
ative or playing an additional role to the þ 61
polymorphism. Finally, sampling variation between the four
studies must also remain a distinct possibility, since type I
errors are a known confounding factor in small case–control
studies.
The situation with regard to EGF þ 61 genotype and
tumor prognosis as evidenced by Breslow thickness re-
mains even less clear-cut, with three studies suggesting
that the GG ‘‘high expression’’ genotype is associated with
greater tumor thickness, with the study by Randerson-Moor
et al (2004) suggesting the converse and one study showing
no association. Again, similar explanations for these dis-
crepancies can be invoked.
Taken together, the two large case–control studies in this
issue of the JID, plus the other two published studies, find
no evidence to support a role of EGF genotype in deter-
mining the susceptibility to CM, whereas its role in progno-
sis remains unclear. Confirmation of a possible role for other
‘‘candidate’’ genetic polymorphisms in CM susceptibility
and/or prognosis is still required in a much larger study.
Because CM is a relatively uncommon cancer, accumula-
tion of sufficient well-defined cases to address this issue—
and to provide a DNA resource bank for future genetic
epidemiological studies on this tumor type—may require a
collaborative network involving several clinical centers and
laboratories, with a parallel collection of controls, appropri-
ately matched for age, sex, ethnicity, and sun exposure.
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